Document:

Exhibit

Exhibit 10.10
[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed
 separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Research Services Agreement

This Research Services Agreement (“Agreement”) is between Augusta University Research Institute, Inc. (“AURI”) a non-profit research and educational corporation, located at Augusta University (“University”), with principal offices at 1120 15th Street, Augusta, Georgia 30912-4810, and NewLink Genetics Corporation, with its principal offices at 2901 South Loop Drive, Ames, Iowa 50010 ("NewLink"). The parties may be referred to individually as “Party” and collectively as the “Parties.” David H. Munn, M.D., shall serve as principal investigator (“PI”) on behalf of AURI. 

Introduction
During the term of this Agreement, NewLink and AURI will collaborate on a research services program for developing and executing in vitro and in vivo bioassays directed to further characterizing PTEN inhibitors identified by NewLink (“Research Services Program”);
NewLink has identified a need to conduct certain tests that: (a) require use of unique or special AURI skills, know-how and facilities that either do not exist elsewhere or are not readily accessible; and (b) involve specialized methods and know-how of a primarily technical nature (“Technical Tests”); and
NewLink has determined that it cannot obtain equivalent Technical Tests from a commercial entity;
AURI has determined that AURI’s performance of the Technical Tests is justified;
The Parties agree that the research services contemplated by this Agreement are of mutual interest and benefit to AURI and to NewLink, and will further the instructional and research objectives of AURI in a manner consistent with its status as a nonprofit, tax-exempt, research and educational institution; and
The Parties agree that the Technical Tests will be performed through a subcontract to University. 
THEREFORE, the Parties agree as follows: 

Terms and Conditions
1.        Performance of Technical Testing Services
1.1.    Technical Testing Services.  During the term of this Agreement, AURI shall develop and perform specialized assays, or shall develop the required techniques and help NewLink to perform such assays, as shall be required or desirable for the characterization of PTEN inhibitors.  These experiments shall be drawn from Exhibit A, “Technical Testing Scope of Work - Menu of Technical Tests”, as amended and updated throughout the course of the Agreement.  Exhibit A contains a general outline of the testing that may potentially be of use to NewLink; and this Exhibit shall be amended and updated before each Technical Test is first performed, to incorporate the actual agreed upon method for performing such Technical Test, to identify any Background Know-How (as defined in the License Agreement) to be used with respect to such Technical Test and to identify the types of Foreground Know-How (as defined in the License Agreement) anticipated to be generated with respect to such Technical Test.  Each set of experiments that is to be performed at AURI under this Agreement shall be mutually agreed upon in advance and in writing by the Parties, on an experiment set-by-experiment set basis, with an agreed budget (supplies, costs, and personnel) developed for each set of desired experiments.  AURI shall invoice 

Exhibit 10.10
[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed
 separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

NewLink for such experiments, and NewLink will pay the invoiced costs of the sets of experiments done at AURI, including associated facilities and indirect costs, in each case to the extent that such set of experiments has been satisfactorily completed and such costs do not exceed the budget therefor by more than [*], unless AURI obtained NewLink’s prior written consent for such cost over-run.  For clarity, sets of experiments that are not mutually agreed upon and reduced to writing under this Agreement with an associated budget, are not required to be performed by AURI on behalf of NewLink.  AURI shall perform all work hereunder in a timely, efficient and professional manner in accordance with industry standards and applicable laws.
1.2.    Reporting and Ownership of Test Results.  AURI agrees to provide to NewLink, on no less than a quarterly basis or as otherwise mutually agreed upon in writing, written reports of Test Results and Foreground Know-How under this Agreement. Exhibit A shall be deemed updated to include all Foreground Know-How included in any such written report.  “Test Results” shall include all data and results of experiments or other work performed by AURI under this Agreement, including raw data, blots, instrumentation printouts, graphs, tables, analytical data and observations.  Upon request by NewLink, AURI shall provide NewLink the original Test Results, and AURI shall be entitled to retain a copy thereof. NewLink shall solely own the Test Results; AURI shall assign and hereby assigns to NewLink all right, title and interest in and to the Test Results.  AURI will obtain all assignments necessary to effectuate such ownership. shall keep and maintain any AURI working notes and laboratory records associated with the experiments or other work performed by AURI under this Agreement in original form and, upon request by NewLink, shall provide NewLink or its designee with copies thereof and/or access thereto.  AURI shall not destroy such notes or records without first offering to transfer them to NewLink or its designee.
1.3.    Licensing.  Pursuant to the License Agreement executed concurrently with this Agreement (“License Agreement”), NewLink has an exclusive license to Licensed Know-How and Licensed Patents (as “Licensed Know-How” and “Licensed Patents” are defined in the License Agreement), subject to AURI’s right to retain a non-exclusive, royalty-free right to use such intellectual property for its own noncommercial research and educational purposes and subject to AURI’s additional retained rights with respect to the Background Know-How, as specified in the License Agreement. In order to facilitate the license by AURI to NewLink of Licensed Know-How, the parties agree that Exhibit A of this Research Services Agreement shall be deemed to also be incorporated into Exhibit A of the License Agreement at the time the design of a proposed experiment under this Research Services Agreement is reduced to writing and signed by both parties and that Exhibit A of the License Agreement shall be deemed to include all confidential Information (other than Test Results) identified in any report provided by AURI as having been generated by AURI pursuant to the Research Services Agreement. 
1.4.    Interpretation and Analysis. In no event will AURI be obligated to provide expert interpretation or analysis of Test Results under this Agreement, but if such interpretation or analysis is provided, it will be deemed to be Foreground Know-How or Licensed Patents (as applicable) and NewLink shall have an exclusive license and other rights thereto (including patent filing, prosecution and enforcement rights) as specified in the License Agreement.
1.5        Technical Contacts. Each Party appoints the following individual to serve as its technical contact during performance of this Agreement. Each Party will notify the other of any change in the technical contact in accordance with the notice requirements of this Agreement.
For AURI:        David. H. Munn, M.D. 
For NewLink:         Mario Mautino, Ph.D.  
1.6.    Test Materials. NewLink will furnish to AURI NewLink’s proprietary compounds to be tested (“Test Materials”).  If NewLink in its discretion provides AURI with any cell lines or other materials to be used in Technical Test, such cell lines or materials shall be deemed to be Test Materials.  AURI will 

Exhibit 10.10
[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed
 separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

provide all other materials needed to perform the Technical Tests. AURI will exercise reasonable care in the handling and storage of Test Materials but will not be liable to NewLink for any loss of or damage to Test Materials unless such loss or damage is due to AURI’s negligence or willful misconduct.  AURI will not provide the Test Materials to any third party or any person not directly involved in the performance of the Technical Tests, AURI will not use the Test Materials for any purposes except for the performance of the Technical Tests.  AURI will return all unused Test Materials to NewLink upon the completion of the Technical Tests or termination of this Agreement or, if earlier, upon NewLink’s request.  The Test Materials shall remain solely owned by NewLink, and nothing herein constitutes a transfer of ownership rights, or grant of any other rights in the Test Materials to AURI. NewLink shall deliver the Test Materials to the following address:
Dr. David Munn        
Augusta University Cancer Center, Room CN4141
1120 15th Street
Augusta, Georgia 30912
1.7.    Funding. AURI shall not use funding from any public or private source other than NewLink in the performance of the Research Services Program.  NewLink acknowledges that PI has an on-going NIH-funded research program on the general biology of PTEN in cancer (not directed to development and testing of new PTEN inhibitors) and this larger program is not covered by this Agreement. 
2.          Confidential Information
AURI shall comply with Article 7 of the License Agreement.  
3.          Inventions        
3.1.    Ownership of Inventions. “Inventions” means those potentially patentable discoveries first conceived or actually reduced to practice by or on behalf of AURI in performance of this Agreement. The Parties anticipate that Inventions by PI are not likely to result from AURI performance of this Agreement. Inventorship shall be determined according to United States patent law.  However, if PI or another employee or agent of University or AURI conceives or reduces to practice any Inventions, then ownership of Inventions shall vest as follows: Inventions solely invented by PI or persons acting under the direction of PI or other employees or agents of AURI or University shall be owned by AURI; Inventions jointly invented by PI or persons acting under the direction of PI or other employees or agents of AURI or University together with  NewLink’s employees, independent contractors or agents shall be jointly owned by AURI and NewLink.  AURI shall obtain all assignments necessary to effectuate such ownership.  AURI shall promptly disclose all Inventions in writing to NewLink, shall provide all additional information reasonably requested by NewLink and shall provide all assistance reasonably requested by NewLink with respect to the filing, prosecution or enforcement of patents or patent applications claiming Inventions, which patents and patent applications are Licensed Patents under the Licensed Agreement.
3.2.    No Implied License.  This Agreement shall not be construed to confer any rights upon either Party by implication, estoppel, or otherwise as to any intellectual property of the other Party not otherwise expressly subject to this Agreement.
4.          Publication.  AURI’s right to publish or publicly present Licensed Know-How are as set forth in Section 7.4 of the License Agreement. 

Exhibit 10.10
[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed
 separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

5.        Compensation 
5.1.     Payment Schedule. In consideration for AURI’s performance of Technical Tests, NewLink will pay to AURI compensation in the amount and manner as negotiated and mutually agreed upon in writing on an experiment set-by-experiment set basis, which writing shall include the work to be done, the costs of the work, and a timeline for Test Results. 
5.2.    Billing Address. AURI will send all invoices to NewLink at the following address: invoices@linkp.com.  
5.3.    Remittance.  Provided that the applicable set of experiments has been satisfactorily completed and the invoiced amounts do not exceed the budget therefor by more than [*], (unless AURI obtained NewLink’s prior written consent for such cost over-run), NewLink will pay, within [*] days of its receipt of the applicable invoice, the invoiced amount to AURI in U.S. currency by check made payable to "Augusta University Research Institute" and mailed to:
	
	
	Augusta University Research Institute, Inc.

	P.O. Box 945552

	Atlanta, Georgia 30394-5552

	Attn: Technical Testing Scope of Work - NewLink/Munn

6.          Term and Termination 
6.1.    Term. This Agreement is effective on the last signature date below and will expire two years from that date, at which time the Parties shall have the option in their sole discretion to renew the Agreement for three additional years, which mutually agreed renewal, if any, shall be in writing signed by both Parties’ authorized representatives.  The Parties agree that this Agreement shall not extend beyond the termination of the License Agreement.
6.2.    Termination. Either Party may terminate this Agreement prior to its expiration date by providing written notice to the other Party at least [*] days in advance of termination.  Upon receipt of written notice of termination, AURI shall, to the extent possible, immediately cease all new work under this Agreement; unless NewLink agrees otherwise in writing, AURI shall remain responsible for completing all work initiated under this Agreement prior to the receipt of written notice of termination. In the event of earlier termination of this Agreement, NewLink will promptly pay AURI for Technical Tests performed, including non-cancellable obligations made by AURI (if NewLink is the terminating party), up to the effective date of termination (or beyond such effective date to the extent necessary for AURI to complete work initiated prior to receipt of written notice of termination), provided that AURI delivers an itemized invoice therefor to NewLink, the applicable Technical Tests have been satisfactorily performed and the invoiced amounts do not exceed the budget therefor by more than [*], (unless AURI obtained NewLink’s prior written consent for such cost over-run).  In the event that the PI becomes unable or unwilling to continue the work under this Agreement, and a mutually acceptable substitute is not available,  AURI or NewLink shall have the option to terminate this Agreement on thirty days written notice.
7.        Disclaimer of Warranties 

Subject to AURI’s compliance with THE LAST SENTENCE OF Section 1.1, ALL TECHNICAL TESTS, TEST RESULTS, AND INVENTIONS UNDER THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS.  Subject to AURI’s compliance with THE LAST SENTENCE OF Section 1.1, AURI MAKES 

Exhibit 10.10
[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed
 separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO ANY MATTER INCLUDING BUT NOT LIMITED TO MERCHANTABILITY, USE OR FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS WITH REGARD TO THE TECHNICAL TESTS, TEST RESULTS, OR INVENTIONS UNDER THIS AGREEMENT. 

8.  Limitation of Liability; Liability to Third Parties; Representations  
8.1.     Limitation of Liability. Except with respect to indemnity obligatIons as set forth in SECTION 8.2 and to breachES of the confidentiality obligations AS DESCRIBED IN SECTION 2, in no event shall either Party be liable to the other party for incidental, consequential, indirect, punitive or special damages arising out of or related to this Agreement, however caused, under any theory of liability, even if advised of the possibility of such damages.
8.2.     Liability to Third Parties. 
(a) NEWLINK agrees to hold AURI and its trustees, officers, employees and agents (collectively, the “AURI Indemnitees”) harmless from all liabilities, damages, and expenses, including reasonable attorney fees, resulting directly from third party claims or demands asserted by third parties against a AURI Indemnitee arising from NEWLINK’S use of the Test Results and/or Inventions.
(b) To be eligible to be indemnified as described in Section 8.2(a), each of the AURI Indemnitees seeking to be indemnified shall provide NewLink with prompt notice of any claim (with a description of the claim and the nature and amount of any such loss) giving rise to the indemnification obligation pursuant to Section 8.2(a) and the exclusive ability to defend such claim (with the reasonable cooperation of AURI Indemnitee(s)).  Each AURI Indemnitee shall have the right to retain its own counsel, at its own expense, if representation by the counsel of NewLink would be inappropriate due to actual or potential differing interests between such AURI Indemnitee(s) and NewLink.  Neither the AURI Indemnitee(s) nor NewLink shall settle or consent to the entry of any judgment with respect to any claim for losses for which indemnification is sought without the prior written consent of the other (not to be unreasonably withheld or delayed); provided however, that NewLink shall have the right to settle or compromise any claim for losses without such prior written consent if the settlement or compromise provides for a full and unconditional release of the AURI Indemnitee(s) and is not materially prejudicial to any AURI Indemnitee’s rights.  NewLink’s obligation to indemnify the AURI Indemnitee(s) pursuant to this Section 8.2 shall not apply to the extent of any losses (a) that arise from the negligence, recklessness, or intentional misconduct of any AURI Indemnitee; or (b) that arise from the breach by AURI of any obligation, representation, warranty or covenant in this Agreement or the License Agreement.
(c) AURI shall be responsible for its own acts in connection with this Agreement, including its negligence, recklessness or intentional misconduct and its breach of any obligation, representation, warranty or covenant in this Agreement. 
8.3     Representation of AURI. AURI represents and warrants that, pursuant to a written subcontract agreement between AURI and University, (a) as between AURI and University, AURI is the sole owner of all inventions, information, materials, data and results made, created, conceived or actually reduced to practice by or on behalf of AURI or University in pursuant to this Agreement and AURI has the right to grant to NewLink the rights and licenses thereto set forth in this Agreement or the License Agreement and (b) University is obligated to comply with AURI’s obligations under this Agreement, including , but not limited to, AURI’s confidentiality obligations under Section 2. 

Exhibit 10.10
[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed
 separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

9.         General Provisions
9.1.     Use of Names. Except as permitted pursuant to Section 7.5 of the License Agreement, neither Party shall use the name of the other in any form of advertising or publicity without the express written permission of the other Party. NewLink shall seek such permission from AURI by submitting the proposed use, well in advance of any deadline, to the University’s Vice President of the Division of Communications and Marketing or designee. 
9.2.     Governing Law.  This Agreement is governed by and construed in accordance with the laws of the State of Georgia, U.S.A., without reference to its conflict of law provisions.
9.3.    Third Party Beneficiaries. This Agreement does not create any rights, or rights of enforcement, in third parties.
9.4.    Severability.  If a court of competent jurisdiction finds any provision of this Agreement legally invalid or unenforceable, such finding will not affect the validity or enforceability of any other provision of this Agreement and the Parties will continue to perform. To the extent possible the Parties shall revise such invalidated Article or part thereof in a manner that will render such provision valid without impairing the Parties’ original interest. 
9.5.    Merger. This Agreement and the License Agreement embody the entire understanding of the Parties and supersedes all previous or contemporaneous communications, either oral or written, between the Parties relating to the subject matter of this Agreement. All terms and conditions of any other instruments, including purchase orders, issued by NewLink at any time to facilitate payment under this Agreement are void.
9.6.    Amendments.  No modification to this Agreement will be effective unless confirmed in a written amendment signed by each Party’s authorized representative.
9.7.    Counterparts.  The Parties may sign this Agreement in counterparts, each of which constitutes an original and all of which together constitute the Agreement. 
9.8.    Assignments.  This Agreement shall bind, and inure to the benefit of, the Parties and any successors to substantially the entire assets of the respective Party. Neither Party may assign this Agreement without first obtaining the prior written consent of the other Party, except that NewLink may make such an assignment or transfer without AURI’s consent to NewLink’s Affiliates or to the successor to all or substantially all of the business of NewLink to which this Agreement relates (whether by merger, acquisition, sale of stock, sale of assets or otherwise).  Any permitted assignment shall be binding on the successors, heirs and assigns of the assigning Party. Any attempted assignment by a Party in violation of the terms of this Section 9.8 shall be null and void. The parties hereby consent to the subcontracting of the work of the Technical Tests under the Agreement to University. 
9.9.    Force Majeure.  Each Party will be excused from performance of the Agreement only to the extent that performance is prevented by conditions beyond the reasonable control of the affected Party. The Party claiming excuse for delayed performance will promptly notify the other Party and will resume its performance as soon as performance is possible.
9.10.    Export Control.  Each party shall comply with all relevant laws, whether United States or foreign, governing the exports and re-exports of technical data or commodities made under this Agreement. 
9.11.    Survival. All terms of this Agreement that are intended to survive termination or expiration in order to be effective shall survive such termination or expiration.

Exhibit 10.10
[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed
 separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

9.12.    Independent Contractor Status.  The Parties are independent contractors with respect to each other and nothing herein shall create any association, partnership, joint venture or agency relationship between them. 
9.13.    Notices.  Any notice given under this Agreement will be in writing and will be effective upon receipt evidenced by: (a) personal delivery; (b) confirmed facsimile transmission; (c) return receipt of postage prepaid registered or certified mail; or (d) delivery confirmation by commercial overnight carrier. All communications will be sent to the addresses set forth below or to such other address designated by a Party by written notice to the other Party in accordance with this section:
AURI:    For matters related to this Agreement:
Sarah J. White
Executive Director 
Augusta University Research Institute, Inc.
CJ-3301, 1120 15th Street
Augusta, Georgia 30912-4810
T: (706) 721-3087
F: (706) 721-6487 

With a copy to:
David H. Munn, M.D. 
Augusta University Cancer Center
1120 15th Street, CN 4141
T: (706) 721-8735
Email: DMUNN@ gru.edu

AURI will send all notices to NewLink under this Agreement to NewLink’s address as follows:
NewLink Genetics Corporation
2503 South Loop Drive
Suite 5100
Ames, Iowa 50010
Attn: Chief Financial Officer
Fax: 515-296-5557

with copies to (which copies shall not constitute notice):

NewLink Genetics Corporation
2503 South Loop Drive
Suite 5100
Ames, Iowa 50010
Attn: Chief Executive Officer
Fax: 515-296-5557

Cooley LLP
3175 Hanover Street
Palo Alto, CA 94304
Attn: Marya A. Postner, Ph.D.
Fax: 650-849-7400

Exhibit 10.10
[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed
 separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

9.14.    Equipment and Supplies.  Unless the Parties agree otherwise, AURI shall retain title to any equipment and supplies purchased with funds provided by NewLink under this Agreement provided that the mutually agreed budget clearly contemplates such purchase.
 9.15.    Conflict of Interest.  University institutional policy requires that persons engaged in sponsored research must disclose potential financial conflicts of interest with such research, including certain consulting, stock ownership, or other relationships with a company which sponsors such research, and that AURI /University must take measures to eliminate or minimize any effects of such potential conflicts on the objectivity of such research. By signing below, PI agrees to comply with University institutional policy and requirements governing conflict of interest.
9.16    Conflicts with Other Agreements.  In the event a conflict arises between a provision or requirement between this Agreement and the License Agreement, the provisions of the License Agreement shall govern.  

[Signatures on next page.]

Exhibit 10.10
[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed
 separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    
IN WITNESS WHEREOF, the duly authorized representatives of the Parties hereby execute this Agreement as of the date appearing below their respective signatures.  

NewLink Genetics Corporation

By: /s/ Charles Link                                3/15/2016                                                    Date
Charles Link, Jr. M.D.                        
Printed Name
Chief Executive Officer                        
Title

Augusta University Research Institute, Inc.

By: /s/ Sarah White                                3/18/2016                                                    Date
Sarah J. White                            
Printed Name
Executive Director                        
Title

Read and Understood by PI: 

/s/ David Munn                            
David. H. Munn, M.D.
David H. Munn, M.D.                    
Name Printed

Exhibit 10.10
[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed
 separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

EXHIBIT A

Technical Testing Scope of Work - Menu of Technical Tests
[*]Exhibit 10.1

 

FORM OF AMENDED AND RESTATED VOTING AGREEMENT

 

This Amended and Restated
Voting Agreement (this “Agreement”) is made as of November 3, 2016 by and between Easterly Acquisition Corp.,
a Delaware corporation (“Parent”) and the undersigned Sungevity, Inc. (the “Company”) stockholder
(“Company Stockholder”).

 

WHEREAS, concurrently
with the execution of this Agreement, Parent, Solaris Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent
(“Merger Sub”), the Company and Sellers Representative have entered into an Amendment No. 2 to the Agreement
and Plan of Merger (as the same may be amended from time to time, the “Merger Agreement”), pursuant to which
Merger Sub will be merged (the “Merger”) with and into the Company with the Company continuing as the surviving
entity and a wholly owned subsidiary of Parent;

 

WHEREAS, as a condition
to its willingness to enter into the Merger Agreement, Parent has required that each Person set forth in Section 5.17 of the Parent
Disclosure Letter execute and deliver this Agreement and agree, among other things, to vote all of their shares of capital stock
of the Company in favor of the approval and adoption of the Merger Agreement and the Merger.

 

WHEREAS, each of
the undersigned has previously entered into a Voting Agreement, dated as of June 28, 2016 (“Prior Voting Agreement”).

 

WHEREAS, to induce
the Parent to enter into the Amendment No. 2 to the Merger Agreement, the Company and the undersigned Company Stockholders desire
to amend and restate the Prior Voting Agreement in the manner set forth in this Agreement.

 

NOW, THEREFORE, in
consideration of the premises and for other good and valuable consideration, the receipt, sufficiency and adequacy of which are
hereby acknowledged, the parties hereto agree as follows:

 

1.           Definitions.
Capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Merger Agreement, as amended.
As used herein the terms:

 

(a)          
“Voting Shares” shall mean all securities of the Company beneficially owned (as such term is defined in Rule
13d-3 under the Exchange Act, but excluding shares of stock underlying unexercised options or warrants) (“Beneficially
Owned” or “Beneficial Ownership”) by Company Stockholder, including any and all securities of the
Company acquired and held in such capacity subsequent to the date hereof (including upon the exercise of options or warrants);
and

 

(b)          “Derivative
Securities” means any securities that are the subject of any derivative or other transaction entered into by any Person,
which gives such person the economic equivalent of ownership of an amount of such securities due to the fact that the value of
the derivative is determined by reference or in relation to the price or value of such securities, irrespective of whether (i)
such derivative conveys or confers to any Person, or otherwise has ascribed to it, any voting rights or voting power or (ii) the
derivative is capable of being or required to be settled by the payment of cash or through the delivery of such securities; 

 

     

     

    

 

2.           Representations
and Warranties of Company Stockholder. Company Stockholder hereby represents and warrants to Parent with respect to Company
Stockholder’s ownership of its Voting Shares set forth on the signature page hereto as follows:

 

(a)          Authority.
If Company Stockholder is a legal entity, Company Stockholder has all requisite power and authority to enter into this Agreement
and to consummate the transactions contemplated hereby. If Company Stockholder is
a natural person, Company Stockholder has the legal capacity to enter into this Agreement.  If
Company Stockholder is a legal entity, this Agreement has been duly authorized, executed and delivered by Company Stockholder.
This Agreement constitutes a valid and binding obligation of Company Stockholder enforceable in accordance with its terms, except
as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’
rights generally and by general principles of equity (regardless of whether considered in a proceeding in equity or at law).

 

(b)          No
Consent. No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Entity or other
Person on the part of Company Stockholder is required in connection with the execution,
delivery and performance of this Agreement. If
Company Stockholder is a natural person, either (i) no consent of Company Stockholder’s spouse is necessary under any “community
property” or other laws for the execution and delivery of this Agreement or the consummation of the transactions contemplated
hereby or (ii) Company Stockholder’s spouse has executed and delivered the spousal consent attached hereto as Exhibit
A. If Company Stockholder is a trust, no consent of any beneficiary is required
for the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby.

 

(c)          No
Conflicts. Neither the execution and delivery of this Agreement, nor the consummation of the transactions contemplated hereby,
nor compliance with the terms hereof, will violate, conflict with or result in a breach of, or constitute a default (with or without
notice or lapse of time or both) under any provision of, any trust agreement, loan or credit agreement, note, bond,
mortgage, indenture, lease or other agreement, instrument, permit, concession, franchise, license, judgment, order, notice, decree,
statute, law, ordinance, rule or regulation applicable to Company Stockholder or to
Company Stockholder’s property or assets that would reasonably be expected to
prevent or delay the consummation of the Merger or that would reasonably be expected to prevent Company Stockholder from fulfilling
its obligations under this Agreement.

 

    	 	2	 

     

    

 

(d)          Ownership
of Shares.  Company Stockholder Beneficially Owns its Voting Shares free
and clear of all Encumbrances. Except pursuant hereto and pursuant to (i) that certain Second Amended and Restated Voting Agreement,
dated as of December 11, 2015, by and among the Company, Company Stockholder and the other stockholders of the Company party thereto
(the “Original Voting Agreement”), (ii) that certain Second Amended and Restated Right of Refusal and Co-Sale
Agreement, dated as of December 11, 2015, by and among the Company, Company Stockholder and the other stockholders of the Company
party thereto (the “Co-Sale Agreement”), and (iii) that certain Sixth Amended and Restated Investors’
Rights Agreement, dated as of December 11, 2015, by and among the Company, Company Stockholder and the other stockholders of the
Company party thereto (the “Investors’ Rights Agreement”), there are no options, warrants or other rights,
agreements, arrangements or commitments of any character to which Company
Stockholder is a party relating to the pledge, acquisition, disposition, transfer or voting of Voting Shares and there are
no voting trusts or voting agreements with respect to the Voting Shares. Company Stockholder does
not Beneficially Own (i) any Voting Shares other than the Voting Shares set forth on Annex A and (ii) any options, warrants
or other rights to acquire any additional shares of Company Common Stock or Company Preferred Stock or any security exercisable
for or convertible into shares of Company Common Stock or Company Preferred Stock, other than as set forth on Annex A (collectively,
“Options”).

 

(e)          Positions.
Neither Company Stockholder nor any of its Affiliates, nor anyone else acting on its or their behalf, has acquired record or beneficial
ownership of, or has a short position or any other interest in, any Voting Securities or debt securities of Parent.

 

3.          
Agreement to Vote Shares; Irrevocable Proxy.

 

(a)          Company
Stockholder agrees during the term of this Agreement to be present and counted and to vote or cause to be voted the Company Voting
Shares that he, she or it Beneficially Owns at any meeting of stockholders of the Company or any adjournment thereof, and to execute
a written consent of stockholders of the Company if stockholders of the Company are requested to vote their shares through the
execution of an action by written consent: (i) in favor of the Merger and the Merger Agreement, at every meeting (or in connection
with any request for action by written consent) of the stockholders of the Company at which such matters are considered and at
every adjournment or postponement thereof; (ii) against any Acquisition Proposal or action, proposal, transaction or agreement
which would reasonably be expected to result in a breach of any covenant, representation or warranty or any other obligation or
agreement of the Company under the Merger Agreement; and (iii) against any action,
proposal, transaction or agreement that would reasonably be expected to impede, interfere with, delay, discourage, adversely affect
or inhibit the timely consummation of the Merger or the fulfillment of the Company’s or Merger Sub’s conditions under
the Merger Agreement or change in any manner the voting rights of any class of shares of the Company (including any amendments
to the Company’s certificate of incorporation or bylaws other than in connection with the Merger).

 

(b)          Company
Stockholder hereby appoints Parent, Avshalom Kalichstein and Darrell Crate and any designee of Avshalom Kalichstein and Darrell
Crate, and each of them individually, as his, her or its proxies and attorneys-in-fact, with full power of substitution and resubstitution,
to vote or act by written consent during the term of this Agreement with respect to the Voting Shares in accordance with Section
3(a). This proxy and power of attorney is given to secure the performance of the duties of Company Stockholder under this Agreement.
Company Stockholder shall take such further action or execute such other instruments as may be necessary to effectuate the intent
of this proxy. This proxy and power of attorney granted by Company Stockholder shall be irrevocable during the term of this Agreement,
shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and, solely with respect to the
transactions described within this Agreement and not regarding voting provisions related to the Company’s Board of Directors
and votes to increase the authorized amount of Company Class A Common Stock (the “Existing Voting Provisions”),
shall revoke any and all prior proxies granted by each Company Stockholder with respect to his, her or its Voting Shares. The power
of attorney granted by Company Stockholder herein is a durable power of attorney and shall survive the dissolution, bankruptcy,
death or incapacity of Company Stockholder. The proxy and power of attorney granted hereunder shall terminate upon the termination
of this Agreement.

 

    	 	3	 

     

    

 

4.           No
Voting Trusts or Other Arrangement. Except for the Original Voting Agreement, Company Stockholder agrees that Company Stockholder
will not, and will not permit any entity under Company Stockholder’s control to, deposit any Voting Shares in a voting trust,
grant any proxies with respect to the Voting Shares or subject any of the Voting Shares to any arrangement with respect to the
voting of the Voting Shares. Except for the previous proxies and attorney in fact with respect to the Existing Voting Provisions
in the Original Voting Agreement, Company Stockholder hereby revokes any and all previous proxies and attorneys in fact with respect
to the Voting Shares.

 

5.           Transfer
and Encumbrance. Company Stockholder agrees that during the term of this Agreement, Company Stockholder will not, directly
or indirectly, transfer, sell, offer, exchange, assign, pledge or otherwise dispose of or encumber (“Transfer”)
any of his, her or its Voting Shares or enter into any contract, option or other agreement with respect to, or consent to, a Transfer
of, any of his, her or its Voting Shares or Company Stockholder’s voting or economic interest therein. Any attempted Transfer
of Voting Shares or any interest therein in violation of this Section 5 shall be null and void. This Section 5 shall not prohibit
a Transfer of Voting Shares by Company Stockholder to (a) an executive officer or director of the Company, (b) any member of Company
Stockholder's immediate family, or to a trust for the benefit of Company Stockholder or any member of Company Stockholder's immediate
family, or upon the death of Company Stockholder, or (c) Company Stockholder’s Affiliate; provided, however, that a Transfer
referred to in this sentence shall be permitted only if, as a precondition to such Transfer, the transferee agrees in a writing,
reasonably satisfactory in form and substance to Parent, to be bound by all of the terms of this Agreement.

 

6.           Standstill.
Without the express, prior written consent of the Parent Board, from and after the date hereof until the earlier of the Closing
or the termination of the Merger Agreement in accordance with the terms thereof (the “Standstill Period”), except
for Company Stockholder’s receipt of Parent Common Stock pursuant to the Merger Agreement, neither Company Stockholder nor
any of its Affiliates shall, directly or indirectly, in any manner:

 

a.           acquire,
offer to acquire or agree to acquire record or beneficial ownership of any securities (or any interest therein or right thereto)
having statutory, organic or contractual voting power, whether or not contingent (“Voting Securities”), of Parent;

 

b.           sell,
transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the
same economic effect as a sale, any Voting Securities (or other securities) of Parent acquired or held by Company Stockholder or
permit any of its Affiliates to do so;

 

c.           enter
into any contract, arrangement, understanding, plan, agreement or commitment (whether oral or written) with respect to any Derivative
Securities of Parent; or

 

d.           advise,
assist, encourage or direct any Person to do (or to advise, assist, encourage or direct any other Person to do) any of the foregoing.

 

    	 	4	 

     

    

 

7.           Appraisal
and Dissenters’ Rights. Company Stockholder hereby waives, and agrees not to assert or perfect, any rights of appraisal
or rights to dissent from the Merger that Company Stockholder may have by virtue of ownership of any Voting Shares.

 

8.           Investor
Agreements. Company Stockholder hereby agrees to the termination of the Original Voting Agreement, the Co-Sale Agreement, the
Investors’ Rights Agreement and any other similar agreements between the Company and Company Stockholder, including any such
agreement granting Company Stockholder investor rights, rights of first refusal, registration rights or director designation rights,
at or immediately prior to the Effective Time, without any liability being imposed on the part of Parent or the Company.

 

9.           Sellers
Representative. Company Stockholder hereby agrees to the appointment of (i) the Sellers Representative named in the Merger
Agreement (or any other Person as the Company Board may decide) to act as Sellers Representative for the benefit of the Selling
Stockholders pursuant to the Merger Agreement and (ii) the Advisory Committee named in the Merger Agreement.

 

10.         Termination.
This Agreement shall terminate upon the earliest to occur of (i) the Effective Time, (ii) the date on which the Merger Agreement
is terminated in accordance with its terms, and (iii) the date of any material modification, waiver or amendment of the Merger
Agreement that affects adversely the consideration payable to stockholders of the Company pursuant to the Merger Agreement as
in effect on the date hereof; provided, however, that in the case of any termination pursuant to the foregoing clause
(i), Sections 7, 15 and 16 shall survive such termination hereof. Except as provided in this Section 10, upon termination of this
Agreement, no party shall have any further obligations or liabilities under this Agreement.

 

11.         No
Agreement as Director or Officer. Company Stockholder is signing this Agreement solely in its capacity as a stockholder of
the Company. If applicable, Company Stockholder does not make any agreement or understanding in this Agreement in Company Stockholder’s
capacity (or in the capacity of any Affiliate, partner or employee of Company Stockholder) as a director or officer of the Company
or any of its Subsidiaries (if Company Stockholder holds such office). If applicable, nothing in this Agreement will limit or affect
any actions or omissions taken by Company Stockholder in his, her or its capacity as a director or officer of the Company, and
no actions or omissions taken in Company Stockholder’s capacity as a director or officer shall be deemed a breach of this
Agreement. Nothing in this Agreement will be construed to prohibit, limit or restrict Company Stockholder from exercising his or
her fiduciary duties as an officer or director to the Company or its stockholders, as applicable.

 

12.          Specific
Enforcement. The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in
accordance with the terms hereof, and, accordingly, that Parent shall be entitled to an injunction or injunctions to prevent breaches
of this Agreement or to enforce specifically the performance of the terms and provisions hereof in the Court of Chancery of the
State of Delaware or any court of the United States located in the State of Delaware without proof of actual damages or otherwise,
in addition to any other remedy to which they are entitled at law or in equity. Company Stockholder hereby further waives (a) any
defense in any action for specific performance that a remedy at law would be adequate and (b) any requirement under any law to
post security or a bond as a prerequisite to obtaining equitable relief.

 

    	 	5	 

     

    

 

13.          Entire
Agreement. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both written
and oral, among the parties with respect to the subject matter hereof, including the Prior Voting Agreement. Any provision of this
Agreement may be amended or waived if, but only if, such amendment or waiver is in writing and is signed, in the case of an amendment,
by each party to this Agreement, or, in the case of a waiver, by the party against whom the waiver is to be effective. No waiver
of any provisions hereof by either party shall be deemed a waiver of any other provisions hereof by such party, nor shall any such
waiver be deemed a continuing waiver of any provision hereof by such party.

 

14.          Notices.
All notices and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by
hand (with written confirmation of receipt), (b) when received by the addressee if sent by a nationally recognized overnight courier
(receipt requested), (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission) if sent
during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient,
or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such
communications must be sent to Parent at Easterly Acquisition Corp., 375 Park Avenue, 21st Floor, New York, NY 10152, Attention:
Avshalom Kalichstein, Facsimile: (646) 383-9413, with a copies (which shall not constitute notice) to (i) Hogan Lovells US LLP,
875 Third Avenue, New York, NY 10022, Attention: Alexander B. Johnson, Facsimile: (212) 918-3100, (ii) Sungevity, Inc., 66 Franklin
St., Oakland, CA 94607, Attention: Andrew Birch, Facsimile: (510) 380-6875, (iii) Sungevity, Inc., 66 Franklin St., Oakland, CA
94607, Attention: General Counsel, Telephone No: (510) 496-5500, Facsimile: (510) 380-6875 and (iv) Orrick, Herrington & Sutcliffe
LLP, The Orrick Building, 405 Howard Street, San Francisco, CA 94105-2669, Attention: Andrew D. Thorpe, Facsimile: (415) 773-5759,
and to Company Stockholder at the addresses set forth on the signature page hereto (or at such other address for a party as
shall be specified in a notice given in accordance with this Section 14).

 

15.          Public
Announcements. Company Stockholder shall not issue any press release or otherwise make any public statement with respect to
this Agreement, the Merger Agreement, the Merger or any other transactions contemplated by the Merger Agreement without the prior
written consent of Parent or except as may be required by applicable Law.

 

16.           Miscellaneous.

 

(a)          This
Agreement shall be governed and construed in accordance with the laws of the State of Delaware without giving effect to the principles
of conflicts of law thereof or of any other jurisdiction.

 

    	 	6	 

     

    

 

(b)          Each
of the parties hereto (a) consents to submit itself, and hereby submits itself, to the personal jurisdiction of the Court of Chancery
of the State of Delaware and any court of the United States located in the State of Delaware, in the event any dispute arises out
of this Agreement, (b) agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request
for leave from any such court, and agrees not to plead or claim any objection to the laying of venue in any such court or that
any judicial proceeding in any such court has been brought in an inconvenient forum, (c) agrees that it will not bring any action
relating to this Agreement or any of the transactions contemplated by this Agreement in any court other than the Court of Chancery
of the State of Delaware or, if under applicable law exclusive jurisdiction is vested in the Federal courts, any court of the United
States located in the State of Delaware and (d) consents to service of process being made through the notice procedures set forth
in Section 14.

 

(c)          EACH
PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY
TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE,
THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED
THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO
THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 16(c).

 

(d)           If
any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other authority
to be invalid, void, unenforceable or against its regulatory policy, the remainder of the terms, provisions, covenants and restrictions
of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and this Agreement
shall be reformed, construed and enforced in such jurisdiction such that the invalid, illegal or unenforceable provision or portion
thereof shall be interpreted to be only so broad as is enforceable.

 

(e)          This
Agreement may be executed in two or more counterparts, all of which shall be considered one and the same agreement and shall become
effective when two or more counterparts have been signed by each of the parties and delivered to the other parties (including by
facsimile or via portable document format (.pdf)), it being understood that all parties need not sign the same counterpart.

 

(f)          Company
Stockholder shall execute and deliver (or cause to be executed and delivered) such additional certificates, instruments and other
documents as may be necessary or desirable, upon the reasonable request of Parent or the Company, to effect the transactions contemplated
by this Agreement, including, without limitation, the Written Consent.

 

(g)          All
Section headings herein are for convenience of reference only and are not part of this Agreement, and no construction or reference
shall be derived therefrom.

 

    	 	7	 

     

    

 

(h)          The
obligations of Company Stockholder set forth in this Agreement shall not be effective or binding upon Company Stockholder until
after such time as the Merger Agreement is executed and delivered by Parent, Merger Sub, the Company and Sellers Representative.
The parties agree that there is not and has not been any other agreement, arrangement or understanding between the parties hereto
with respect to the matters set forth herein.

 

(i)          No
party to this Agreement may assign any of its rights or obligations under this Agreement without the prior written consent of the
other parties hereto. Any assignment contrary to the provisions of this Section 16(i) shall be null and void.

 

[Remainder of this page intentionally left
blank]

 

    	 	8	 

     

    

 

IN WITNESS WHEREOF, the
parties hereto have executed and delivered this Agreement as of the date first written above.

 

	 	PARENT:
	 	 
	 	EASTERLY ACQUISITION CORP.
	 	 
	 	By:	 
	 	Name: Avshalom Kalichstein
	 	Title: Chief Executive Officer

 

[Amended and Restated Voting Agreement
Signature Page]

 

     

     

    

 

 

IN WITNESS WHEREOF, the
parties hereto have executed and delivered this Agreement as of the date first written above.

 

	 	COMPANY STOCKHOLDER:
	 	 
	 	[                                                             ]
	 	 
	 	By:	 
	 	Name: 
	 	Title: 
	 	Address: 

 

Company Class A Common
Stock: ____________

 

Company Class B Common
Stock: ____________

 

Company Series A Preferred
Stock: ___________

 

Company Series B Preferred
Stock: ___________

 

Company Series C Preferred
Stock: ___________

 

Company Series D Preferred
Stock: ___________

 

[Amended and Restated Voting Agreement
Signature Page]

 

     

     

    

 

Exhibit
A

 

CONSENT
OF SPOUSE

 

I, ____________________,
spouse of ______________________ (“Company Stockholder”), have read and hereby approve the foregoing Amended
and Restated Voting Agreement. In order to facilitate the Merger as set forth in the Merger Agreement, I hereby agree to be irrevocably
bound by the Amended and Restated Voting Agreement and further agree that any community property or similar interest that I may
have in the Voting Shares (as defined therein) shall be similarly bound by the Amended and Restated Voting Agreement. I hereby
appoint my spouse as my attorney-in-fact with respect to any amendment or exercise of any rights under the Amended and Restated
Voting Agreement.

 

	 	 
	 	Spouse of Company Stockholder
	 	(if applicable)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]